Krsnaa Diagnostics (KRSNAA) Q4 24/25 earnings summary

Executive summary

• Achieved 16% year-over-year revenue growth in FY 2025, reaching INR 7,172 million, with strong expansion in radiology and pathology segments and increased patient footfalls.

• Served over 19 million patients and conducted 61 million tests, reflecting operational maturity and network optimization.

• Retail strategy gained momentum, expanding touchpoints 4X across four states, with retail contributing 3.5% of Q4 revenue and targeting 700 centers by FY27E.

• Recognized with multiple industry awards, including Best Diagnostic Lab Chain of the Year (West) and National Diagnostic Chain of the Year.

• Audited standalone and consolidated financial results for FY 2025 were approved with an unmodified auditor's opinion.

Financial highlights

• FY 2025 consolidated revenue reached INR 7,172 million (+16% YoY); EBITDA INR 1,958 million (+34% YoY, 27% margin); net profit INR 776 million (+37% YoY, 11% margin).

• Q4 FY 2025 revenue was INR 1,861 million, up 12% year-over-year; EBITDA at INR 542 million (29% margin), net profit at INR 206 million (11% margin).

• Board recommended a dividend of INR 2.75 per share (55% of face value), pending AGM approval.

• Total assets as of March 31, 2025, stood at INR 12,816 million; equity at INR 8,828 million; gross debt at INR 1,655 million; cash and equivalents at INR 1,760 million.

• Basic EPS (consolidated) for FY 2025 was INR 24.04, up from INR 17.90 in FY 2024.

Outlook and guidance

• Targeting continued double-digit revenue growth and margin improvement in FY 2026, with aspirations to surpass FY 2025 growth.

• Retail revenue expected to rise to 5-8% of total in FY 2026, with a long-term goal of 30% B2C mix in retail.

• Plans to expand retail network to 700 centers and B2B collaborations to ~3,500 by FY27E.

• Receivable days expected to normalize to 90-100 by end of FY 2026, with significant improvement anticipated in the coming quarters.

• Management expects no material impact from ongoing tax disputes on the financial position or performance.